Exenatide improves glucocorticoid-induced glucose intolerance in mice
Ruiying Zhao1,2*, Enrique Fuentes-Mattei1,2*, Guermarie Velazquez-Torres1,3, Chun-Hui Su1,2, Jian Chen1, Mong-Hong Lee1,2, Sai-Ching Jim Yeung4,51Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Program in Genes and Development, 3Progra...
Guardado en:
Autores principales: | Ruiying Zhao, Enrique Fuentes-Mattei, Guermarie Velazquez-Torres, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d1956e1105bc444082d4e5ddd2627293 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell L, et al.
Publicado: (2013) -
Frequency of diabetes, impaired fasting glucose, and glucose intolerance in high-risk groups identified by a FINDRISC survey in Puebla City, Mexico
por: Hirales-Tamez O, et al.
Publicado: (2012) -
Treating statin-intolerant patients
por: Pigna G, et al.
Publicado: (2011) -
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud A, et al.
Publicado: (2015) -
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann KV, et al.
Publicado: (2014)